Please assess the completion status of the following clinical trial:

Trial Title: Single-dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed diagnosis of systemic juvenile idiopathic arthritis as per ILAR definition that must have occurred at least 2 months prior to enrollment with onset of disease \< 16 years of age:~   * Arthritis in one or more joints with or preceded by fever of at least 2 weeks duration that is documented to be daily/quotidian for at least 3 days and accompanied by one or more of the following:~  * evanescent nonfixed erythematous rash,~  * generalized lymph node enlargement,~  * hepatomegaly and/ or splenomegaly,~  * serositis~2. Parent's or legal guardian's written informed consent and child's assent, if appropriate, or patient's informed consent for ≥ 18 years of age~3. Male and female patients aged ≥ 2 to \< 20 years of age~4. Active disease at the time of enrollment defined as follows:~   * At least 2 joints with active arthritis~  * Documented spiking, intermittent fever (body temperature \> 38°C) for at least 1 day during the screening period within 1 week before first canakinumab/placebo dose~  * C-reactive protein (CRP) \> 30 mg/L (normal range \< 10 mg/L)~5. Naïve to canakinumab~6. Other protocol defined inclusion criteria may apply~Exclusion Criteria:~Patients who fulfilled one or more of the following criteria were not eligible for inclusion in this study:~1. Pregnant or nursing (lactating) female patients~2. Female patients having reached sexual maturity unless their career, lifestyle, or sexual orientation precluded intercourse with a male partner and/or they were using an acceptable method of contraception~3. History of hypersensitivity to study drug or to biologics.~4. Diagnosis of active macrophage-activation syndrome (MAS) (Ravelli, Magni-Manzoni and Pistorio 2005) within the last 6 months~5. With active or recurrent bacterial, fungal or viral infection, including patients with evidence of human immunodeficiency virus (HIV) infection, hepatitis B or hepatitis C infection~6. Other protocol defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 19 Years
- Healthy Volunteers: f

Study Arms:
- Canakinumab (Type: EXPERIMENTAL): Patients received a single dose of subcutaneous(sc) injection of canakinumab (4 mg/kg) on Day 1. Maximal total single dose of canakinumab allowed was 300 mg. Any patient who required a dose greater than 150 mg (patients\>37.5 kg) received two sc injections.
- Placebo (Type: PLACEBO_COMPARATOR): Patients received a single dose matching placebo of canakinumab on day 1.

Based on this trial design, predict the completion outcome and termination type (if applicable).